Trial Profile
Study of sarpogrelate in reducing incidence of contrast induced nephropathy (CIN) in patients with chronic kidney disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2018
Price :
$35
*
At a glance
- Drugs Sarpogrelate (Primary)
- Indications Renal impairment
- Focus Therapeutic Use
- 12 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association